Interaction between the STAT4 rs11889341(T) risk allele and smoking confers increased risk of myocardial infarction and nephritis in patients with systemic lupus erythematosus


Objective To investigate how genetics influence the risk of smoking-related systemic lupus erythematosus (SLE) manifestations.

Methods Patients with SLE (n\textsubscript{discovery cohort} = 776, n\textsubscript{replication cohort} = 836) were genotyped using the 200K Immunochip single nucleotide polymorphisms (SNP) Array (Illumina) and a custom array. Sixty SNPs with SLE association (p<5.0×10\textsuperscript{-8}) were analysed. Signal transducer and activator of transcription 4 (STAT4) activation was assessed in in vitro stimulated peripheral blood mononuclear cells from healthy controls (n=45).

Results In the discovery cohort, smoking was associated with myocardial infarction (MI) (OR 1.96 (95% CI 1.09 to 3.55)), with a greater effect in patients carrying any rs11889341 STAT4 risk allele (OR 2.72 (95% CI 1.24 to 6.00)) or two risk alleles (OR 8.27 (95% CI 1.09 to 64.27)). Smokers carrying the risk allele also displayed an increased risk of nephritis (OR 1.47 (95% CI 1.06 to 2.03)). In the replication cohort, the high risk of MI in smokers carrying the risk allele and the association between the STAT4 risk allele and nephritis in smokers were confirmed (OR 6.19 (95% CI 1.29 to 29.79) and 1.84 (95% CI 1.05 to 3.29), respectively). The interaction between smoking and the STAT4 risk allele resulted in further increase in the risk of MI (OR 2.14 (95% CI 1.01 to 4.62)) and nephritis (OR 1.53 (95% CI 1.08 to 2.17)), with 54% (MI) and 34% (nephritis) of the risk attributable to the interaction. Levels of interleukin-12-induced phosphorylation of STAT4 in CD8\textsuperscript{+} T cells were higher in smokers than in non-smokers (mean geometric fluorescence intensity 1063 vs 565, p=0.0063). Lastly, the IL12A rs564799 risk allele displayed association with MI in both cohorts (OR 1.53 (95% CI 1.01 to 2.31) and 2.15 (95% CI 1.08 to 4.26), respectively).

Conclusions Smoking in the presence of the STAT4 risk gene variant appears to increase the risk of MI and nephritis in SLE. Our results also highlight the role of the IL12–STAT4 pathway in SLE-cardiovascular morbidity.

Key messages

What is already known about this subject?

- Neither traditional nor systemic lupus erythematosus (SLE)-related risk factors can fully account for the excess cardiovascular disease risk seen in patients with SLE, but interactions between traditional and SLE-specific risk factors have been scarcely investigated.

What does this study add?

- Our results show that the signal transducer and activator of transcription 4 (STAT4) risk allele rs11889341 enhances the effect of smoking on the risk of myocardial infarction and nephritis and that smoking is associated with increased interleukin (IL)-12-induced phosphorylation of STAT4 in CD8\textsuperscript{+} T cells.

- We further demonstrate that the IL12A SLE risk variant rs564799 is associated with an increased risk of myocardial infarction, which further highlights the importance of the IL12–STAT4 pathway in the aetiology of cardiovascular morbidity in SLE.

How might this impact on clinical practice or future developments?

- Our results suggest that genetic profiling of patients with SLE may be useful for predicting comorbidities of the disease, impact of environmental factors and for targeted smoking cessation interventions.

INTRODUCTION

Systemic lupus erythematosus (SLE) is a disease characterised by loss of tolerance to self-antigens, formation of immune complexes and an activated type I interferon (IFN) system. A widely accepted view of the aetiology of SLE is that environmental factors trigger the disease in genetically susceptible individuals. The genetic background is complex, with more than 100 single nucleotide polymorphisms (SNPs) associated with risk
for SLE. Exposure to certain environmental factors, including ultraviolet radiation and viral infections, is associated with SLE development and flare-ups of the disease. Several studies have evaluated smoking as a risk factor for SLE, with the largest meta-analysis to date showing a modest risk increase. While the results are not confirmed in prospective studies, both Cozier and Barbhaiya et al observed a trend of increased risk in smokers. The most extensive prospective study involving 286 cases with SLE demonstrated an association between smoking and development of SLE with increased anti-dsDNA, but no risk of overall SLE.

Although death from active SLE has decreased since the 1950s, the mortality rate still exceeds that of the general population, with cardiovascular morbidity remaining considerably high and a strong risk factor for premature mortality. Both traditional and SLE-related risk factors, such as hypertension, nephritis and high disease activity have been identified as risk factors, but cannot fully account for the excess cardiovascular disease (CVD) risk seen in patients with SLE. To fully explain the aetiology of SLE or its comorbidities such as CVD, gene–environment interactions may be essential to consider. In rheumatoid arthritis, there is compelling evidence of a strong interaction between the HLA-DRB1*04 shared epitope and smoking on the development of anticitrullinated protein autoantibodies and a high prevalence of cardiovascular events (CVE).

In SLE, a few studies have investigated the interaction between genetic risk factors and smoking on the development of the disease. Recently, Cui et al demonstrated that an additive interaction between smoking and the cumulative genetic risk of SLE increases the risk of the disease. However, gene–smoking interactions on the development of specific manifestations or co-morbidities of SLE have been scarcely studied. This study, therefore, aims to investigate the effect of smoking on the development of specific manifestations of SLE, including CVE, end-stage renal disease (ESRD) and nephritis, and examine how the effect is modulated by the presence of genetic variants associated with an increased risk of SLE development.

### METHODS

**Patients of the discovery and replication cohort**

The discovery cohort included 774 patients with SLE from Sweden. The replication cohort included 836 patients from Norway and Denmark. All subjects fulfilled ≥4 American College of Rheumatology (ACR)—82 and ACR-97 classification criteria for SLE and were of European descent. Clinical characteristics of the cohorts are described in table 1 and online supplemental.

### Table 1 Prevalence of clinical manifestations in smokers (n=371) and non-smokers (n=387) in the discovery cohort

<table>
<thead>
<tr>
<th>Smokers, n (%)</th>
<th>Non-smokers, n (%)</th>
<th>OR (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at last follow-up, mean (SD)</td>
<td>55 (15)</td>
<td>50 (17)</td>
<td>1.00 (0.74 to 1.34)</td>
</tr>
<tr>
<td>Disease duration, mean (SD)</td>
<td>17 (11)</td>
<td>16 (12)</td>
<td>1.00 (0.96 to 1.04)</td>
</tr>
<tr>
<td>Male sex</td>
<td>49 (13)</td>
<td>48 (13)</td>
<td>0.94 (0.61 to 1.45)</td>
</tr>
<tr>
<td>Male sex</td>
<td>49 (13)</td>
<td>48 (13)</td>
<td>1.19 (0.75 to 1.88)</td>
</tr>
<tr>
<td>ACR 1982 classification criteria</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 Malaise</td>
<td>205 (55)</td>
<td>211 (57)</td>
<td>1.00 (0.74 to 1.34)</td>
</tr>
<tr>
<td>2 Discoid rash</td>
<td>83 (22)</td>
<td>80 (21)</td>
<td>1.00 (0.96 to 1.04)</td>
</tr>
<tr>
<td>3 Photosensitivity</td>
<td>262 (71)</td>
<td>246 (65)</td>
<td>1.00 (0.96 to 1.04)</td>
</tr>
<tr>
<td>4 Oral ulcer</td>
<td>103 (28)</td>
<td>96 (25)</td>
<td>1.00 (0.96 to 1.04)</td>
</tr>
<tr>
<td>5 Arthritis</td>
<td>306 (82)</td>
<td>301 (81)</td>
<td>1.00 (0.96 to 1.04)</td>
</tr>
<tr>
<td>6 Serositis</td>
<td>179 (48)</td>
<td>165 (45)</td>
<td>1.00 (0.96 to 1.04)</td>
</tr>
<tr>
<td>7 Renal disorder</td>
<td>129 (35)</td>
<td>132 (36)</td>
<td>1.00 (0.96 to 1.04)</td>
</tr>
<tr>
<td>8 Neurological disorder</td>
<td>33 (9)</td>
<td>40 (10)</td>
<td>1.00 (0.96 to 1.04)</td>
</tr>
<tr>
<td>9 Haematological disorder</td>
<td>213 (57)</td>
<td>258 (70)</td>
<td>1.00 (0.96 to 1.04)</td>
</tr>
<tr>
<td>10 Immunological disorder</td>
<td>245 (66)</td>
<td>256 (69)</td>
<td>1.00 (0.96 to 1.04)</td>
</tr>
<tr>
<td>Anti-dsDNA</td>
<td>224 (61)</td>
<td>231 (63)</td>
<td>1.00 (0.96 to 1.04)</td>
</tr>
<tr>
<td>11 ANA</td>
<td>364 (98)</td>
<td>367 (99)</td>
<td>1.00 (0.96 to 1.04)</td>
</tr>
<tr>
<td>Renal variables</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WHO class I–II</td>
<td>12 (5)</td>
<td>20 (8)</td>
<td>1.00 (0.96 to 1.04)</td>
</tr>
<tr>
<td>WHO class III–IV</td>
<td>62 (21)</td>
<td>71 (22)</td>
<td>1.00 (0.96 to 1.04)</td>
</tr>
<tr>
<td>WHO class V</td>
<td>15 (6)</td>
<td>16 (6)</td>
<td>1.00 (0.96 to 1.04)</td>
</tr>
<tr>
<td>Other*</td>
<td>11 (4)</td>
<td>6 (2)</td>
<td>1.00 (0.96 to 1.04)</td>
</tr>
<tr>
<td>ESRD</td>
<td>14 (4)</td>
<td>14 (4)</td>
<td>1.00 (0.96 to 1.04)</td>
</tr>
<tr>
<td>Cardiovascular events</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MI</td>
<td>39 (11)</td>
<td>19 (5)</td>
<td>1.96 (1.09 to 3.55)</td>
</tr>
<tr>
<td>ICVD</td>
<td>45 (12)</td>
<td>30 (8)</td>
<td>1.37 (0.84 to 2.24)</td>
</tr>
<tr>
<td>VTE</td>
<td>61 (16)</td>
<td>52 (14)</td>
<td>1.14 (0.76 to 1.71)</td>
</tr>
<tr>
<td>Clinical APS</td>
<td>68 (20)</td>
<td>61 (18)</td>
<td>1.00 (0.73 to 1.60)</td>
</tr>
<tr>
<td>Anti-β2GPI I gM</td>
<td>58 (19)</td>
<td>57 (18)</td>
<td>0.98 (0.69 to 1.39)</td>
</tr>
<tr>
<td>Anti-β2GPI I IgG</td>
<td>8 (3)</td>
<td>11 (2)</td>
<td>0.96 (0.36 to 2.55)</td>
</tr>
<tr>
<td>LA</td>
<td>62 (23)</td>
<td>57 (21)</td>
<td>1.19 (0.79 to 1.80)</td>
</tr>
<tr>
<td>aCL-IgG</td>
<td>86 (26)</td>
<td>90 (28)</td>
<td>1.05 (0.70 to 1.59)</td>
</tr>
<tr>
<td>aCL-IgM</td>
<td>34 (14)</td>
<td>33 (13)</td>
<td>0.96 (0.36 to 2.55)</td>
</tr>
</tbody>
</table>

Logistic regression models were used to assess differences between smokers and non-smokers. All analyses were adjusted for age at last follow-up and disease duration.

*p<0.05 (unadjusted for multiple comparisons) in bold.

*Patients with biopsies displaying signs of nephritis but not meeting the criteria for any of the above classes were classified as other.

ACR, American College of Rheumatology; ANA, antinuclear antibodies; Anti-β2GPI-I, anti-β2-glycoprotein I; APS, antiphospholipid syndrome; dsDNA, double-stranded DNA; ESRD, end-stage renal disease; ICVD, ischaemic cerebrovascular disease; LA, lupus anticoagulant; MI, myocardial infarction; VTE, venous thromboembolism.
Genotyping and selection of SNPs

Genotyping of the discovery cohort was performed using the Illumina 200K Immunochip SNP array, for details, see online supplemental file. SNPs previously associated with SLE at genome-wide significance in the European population were selected. For SNPs not included on the Immunochip, the SNP-proxy with the highest linkage disequilibrium (LD) ($r^2 \geq 0.96$) was selected. All SNPs were filtered for independent signals, removing the variant with the lowest SLE-OR for SNPs in LD ($r^2 > 0.2$). In total, 4 HLA and 56 non-HLA SNPs were investigated for associations with MI (online supplemental table 2). Individuals in the replication cohort were genotyped for three single nucleotide variants using a custom assay on the MassARRAY system (see online supplemental file).

Interleukin-12-induced phosphorylation of STAT4

Interleukin 12 (IL-12)-induced phosphorylation of signal transducer and activator of transcription 4 (pSTAT4) was previously determined in 72 healthy blood donors from Uppsala Bioreource using flow cytometry. Smoking data were available from 45 of these donors, of which 20 were past or current smokers and 25 were non-smokers.

Statistical analysis

To investigate associations between smoking and clinical manifestations, logistic regression models were used. As smoking was associated with longer disease duration and higher age at follow-up (table 1), these variables were included as covariates. In analysis of associations between genetic variants and MI, SNPs were first analysed separately. Next, all variants demonstrating a positive association with MI were included in a forwards conditional multiple regression model. All analyses were adjusted for age and disease duration. Results considered statistically significant (unadjusted $p<0.05$) were reanalysed in the replication cohort using the same statistical model and covariates. Meta-analyses were performed on the two datasets and multiplicative and additive interactions between the STAT4 risk allele and smoking were studied in a combined dataset through addition of a STAT4-smoking interaction term in the logistic models and by calculating the attributable proportion due to interaction, respectively.

RESULTS

Smoking is modestly associated with MI

Initially, we assessed the association between smoking and clinical manifestations (table 1). We found no evidence of any associations between smoking and the ACR criteria, except the haematological criterion, which was less prevalent in smokers (table 1). Elevated levels of red and white blood cells in smokers is a well-known phenomenon. Smoking was not associated with a history of DVT or ICVD, however, a significant association between smoking and MI was observed (OR 1.96 (95% CI 1.09 to 3.55), $p=0.0255$) (table 1).

Increased risk of MI in SLE-smokers with the STAT4 risk allele

Next, we asked whether there are sub-groups of patients in which smoking plays a more prominent role in MI development. We initially examined 60 SNPs with established association with SLE ($p<5.0 \times 10^{-8}$) for association with MI (online supplemental table 2). We found that the Neutrophil Cytosolic Factor 2 (NCF2), Interleukin-12A (IL12A) and STAT4 risk alleles displayed independent, positive association with MI (table 2). In addition, patients carrying two alleles of both the STAT4 and the IL12A risk variants (n=37, 4.9% of the patients) displayed a substantially higher prevalence of MI compared with those with any other allele combination (27% vs 7%) (OR 5.88 (95% CI 2.44 to 14.17), $p=7.9 \times 10^{-5}$) (figure 1A).

Next, we stratified patients by smoking status to determine whether each of the three SNPs displayed stronger association with MI in smokers. No significant associations were found for the NCF2 or IL12A risk alleles (OR 1.58 (95% CI 0.89 to 2.78), $p=0.12$ and OR 1.36 (95% CI 0.89 to 2.08), $p=0.15$, respectively). However, the STAT4 risk allele demonstrated a stronger association in smokers (OR 2.45 (95% CI 1.46 to 4.19), $p=0.00086$) (figure 2A).

Next, we assessed the association between smoking and MI in patients carrying the STAT4 risk allele and observed an almost 3-fold increase in risk for the smokers compared with the non-smokers (OR 2.72 (95% CI 1.24 to 6.00), $p=0.013$). In patients carrying two risk alleles, the risk was more than eightfold higher for smokers (OR 8.27 (95% CI 1.48 to 46.27), $p=0.016$). In contrast, we could not demonstrate a significant association between smoking and MI.

Table 2: Associations between SLE risk SNPs and myocardial infarction in the discovery and replication cohort

<table>
<thead>
<tr>
<th>SNP</th>
<th>Gene name</th>
<th>Discovery cohort (n=763)</th>
<th>Replication cohort (n=836)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Risk allele frequency</td>
<td>Risk allele frequency</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HWE p</td>
<td>MI+</td>
</tr>
<tr>
<td>n17849502</td>
<td>NCF2</td>
<td>0.013</td>
<td>0.12</td>
</tr>
<tr>
<td>n11889341</td>
<td>STAT4</td>
<td>0.81</td>
<td>0.44</td>
</tr>
<tr>
<td>n564799</td>
<td>IL12A</td>
<td>0.29</td>
<td>0.68</td>
</tr>
</tbody>
</table>

Using a forward conditional multiple regression model, 60 genetic variants with previously established association with SLE ($p<5.0 \times 10^{-8}$, online supplemental table 2) were analysed for associations with myocardial infarction in the discovery cohort. The table shows SNPs included in the final model. These SNPs were subsequently analysed in the replication cohort. Age at follow-up and disease duration were included as covariates. $P<0.05$ (unadjusted for multiple comparisons) in bold. HWE was tested on all patients in the discovery and replication cohorts, respectively.

HWE, Hardy-Weinberg equilibrium; IL12A, Interleukin12A; MI, myocardial infarction; NCF2, neutrophil cytosolic factor 2; SLE, systemic lupus erythematosus; SNPs, single-nucleotide polymorphisms; STAT4, signal transducer and activator of transcription 4.

in patients without the risk allele (OR 1.20 (95% CI 0.49 to 2.96) p=0.53).

As patients with nephritis have previously been shown to have a higher prevalence of both MI and the STAT4 risk allele,25–27 we hypothesised that the results would be similar if using nephritis, rather than MI, as the outcome variable. Without stratifying for smoking, the association between the STAT4 risk allele and nephritis reached suggestive significance (OR 1.23 (95% CI 0.98 to 1.54), p=0.072). The effect was more pronounced in the smokers only (OR 1.47 (95% CI 1.06 to 2.03), p=0.020).

In addition, we found moderate evidence that patients with nephritis carrying the STAT4 risk allele were at a greater risk of developing ESRD (OR 1.85 (95% CI 0.96 to 3.59), p=0.068), and this risk was enhanced in smokers (OR 2.52 (95% CI 1.04 to 6.10), p=0.040) (figure 2B). Of note, despite the non-smoking group including more patients with nephritis (n=140 vs n=129), no evidence of an association between the STAT4 risk allele and nephritis or ESRD could be demonstrated in this group (OR 1.07 (95% CI 0.77 to 1.46), p=0.70 and OR 1.10 (95% CI 0.38 to 3.16), p=0.86, respectively).

To validate our significant findings, we performed the same analyses in an independent cohort of patients with SLE (online supplemental table 1). Analysis of the genetic variants demonstrated that the IL12A risk allele was the only gene variant significantly associated with MI when not accounting for smoking

Interaction between STAT4 risk allele and smoking results in a higher risk of MI and nephritis

We subsequently performed interaction analyses on all patients and found a significant multiplicative interaction between the STAT4 risk allele and smoking on the development of MI (OR 2.14 (95% CI 1.01 to 4.62), p=0.049) as well as nephritis (OR 1.53 (95% CI 1.08 to 2.17), p=0.020) (online supplemental table 3). Next, we examined additive interaction and observed an attributable proportion due to interaction of 0.54 (95% CI 0.24 to 0.83, p=0.00019) and 0.34 (95% CI 0.080 to 0.61, p=0.0051) for MI and nephritis, respectively.

To determine whether the effect of the STAT4 risk allele on nephritis in smokers could explain the association with MI, we performed stratification of the combined dataset and investigated the association between the STAT4 risk allele and MI in smokers and non-smokers without nephritis. In the smokers, the association between the STAT4 risk allele and nephritis remained significant (n=428, OR 2.43 (95% CI 1.40 to 4.27), p=0.0017) (figure 3). Similarly, the association between the STAT4 risk allele and nephritis in smokers remained significant after excluding patients with MI from the analysis (n=623, OR 1.54 (95% CI 1.20 to 1.98), p=0.00076).

Lastly, as both SLE risk alleles in STAT4 and smoking have shown association with the development of aPL in previous studies,28 29 we assessed the association between the STAT4 risk allele and aPL in smokers, however, it was not significant (OR 1.56 (95% CI 0.71 to 3.72, p=0.26). Next, we performed a multiple regression model in the smoking group including the STAT4 risk allele, any aPL, nephritis, age at follow-up, and disease duration as covariates. We found the association between the STAT4 risk allele and MI to remain significant (OR 3.26 (95% CI 1.15 to 9.20), p=0.026), whereas neither aPL nor
patients with SLE. To investigate whether smoking also influences the levels of pSTAT4 expression that have been demonstrated previously in individuals who smoke and carry the risk allele is connected to the nucleus where it induces expression of hundreds of genes, resulting in production of IFN-γ, T-helper type 1 and 17 differentiation and activation of monocytes. Increased STAT4 mRNA expression is associated with increased cardiovascular damage in patients with SLE and several studies on animal models indicate a link between STAT4 and the development of atherosclerosis. The mechanism of how smoking leads to increased levels of activated STAT4 is unclear, however, we speculate that epigenetics may constitute the bridge between smoking, genetics and SLE. It is well known that smoking affects both overall DNA methylation and specific gene promoters. Epigenetic regulation is further believed to play an important role both in cardiovascular biology and in SLE development. Whether smoking is associated with epigenetic changes in SLE-specific genes, and if such changes are associated with specific manifestations of SLE, deserves further studies.

The analyses of individual SLE risk alleles identified the SLE-risk SNP IL12A to be associated with an increased risk of MI, and that patients in the discovery and replication cohort carrying two alleles of both the IL12A and STAT4 risk SNPs had a more than fivefold and eightfold risk of MI, respectively. The IL12A SNP is located within the fourth intron of the IL12A gene, which encodes the p35 subunit of the IL-12 protein. On binding to its receptor, IL-12 induces phosphorylation of STAT4. We speculate that epigenetics may constitute the bridge between smoking, genetics and SLE.

**DISCUSSION**

In the present study, we demonstrate that smoking substantially increases the risk of MI in a subset of patients with SLE carrying a variant of the STAT4 SLE-risk gene. In both the discovery and replication cohorts, the effect size increased with an increasing number of STAT4 risk alleles, with smoking giving rise to a more than 8-fold risk of MI in homozygous individuals. We believe that our results add important knowledge in the understanding of how SLE-risk alleles can modulate the effect of traditional risk factors.

The prevalence of MI is higher in SLE patients with nephritis than patients without renal manifestations and SLE-risk alleles in STAT4 have previously been linked to both nephritis and severe renal insufficiency. We, therefore, speculated that the smoking-STAT4 risk allele interaction did not directly affect MI, but rather, was a consequence of an interaction between the STAT4 risk allele and smoking on the development of nephritis. Indeed, we found that this gene-environment combination also results in a higher risk of nephritis, as well as ESRD. Interestingly, however, the STAT4 risk allele/smoking effect on MI did not decrease when adjusting the model for nephritis or when completely removing the patients with nephritis from the analysis. Similarly, the effect of the STAT4 risk allele/smoking on nephritis remained significant after excluding all patients with MI from the analysis, indicating that the associations were independent.

Based on these results, we hypothesised that the increased risk in individuals who smoke and carry the risk allele is connected to the levels of activated STAT4 in these individuals. Hagberg et al. have shown that the rs7574865 STAT4 risk allele—which is in perfect LD (r²=1.00) with the SNP used in this study—is associated with increased levels of pSTAT4 in activated CD8+ T cells of SLE patients. Therefore, we assessed whether smoking elevates pSTAT4 in this cell type and found that the levels were almost twofold higher in smokers. This observation is in line with previous findings by Di Stefano et al., who demonstrated higher levels of pSTAT4 in bronchial T cells from healthy smokers compared with non-smokers. When STAT4 is activated and phosphorylated, it homodimerises and translocates to the nucleus where it induces expression of hundreds of genes, resulting in production of IFN-γ, T-helper type 1 and 17 differentiation and activation of monocytes. Increased STAT4 mRNA expression is associated with increased cardiovascular damage in patients with SLE and several studies on animal models indicate a link between STAT4 and the development of atherosclerosis. The mechanism of how smoking leads to increased levels of activated STAT4 is unclear, however, we speculate that epigenetics may constitute the bridge between smoking, genetics and SLE. It is well known that smoking affects both overall DNA methylation and specific gene promoters. Epigenetic regulation is further believed to play an important role both in cardiovascular biology and in SLE development.

Whether smoking is associated with epigenetic changes in SLE-specific genes, and if such changes are associated with specific manifestations of SLE, deserves further studies.

**Figure 3** The prevalence of myocardial infarction (MI) in patients without nephritis. To investigate whether the association between the rs11889341 (STAT4) allele and MI was dependent on the association between the STAT4–nephritis association, all patients with nephritis were excluded and the prevalence of MI was subsequently plotted for smoking (A) and non-smoking (B) patients with 0, 1 or 2 of the STAT4 risk allele. Patients with 0, 1 or 2 risk alleles in each group were compared using logistic regression, adjusting for age at follow-up and disease duration. STAT4, signal transducer and activator of transcription 4.

**Figure 4** Levels of pSTAT4 in CD8+ T cells after stimulation with IL-12. The levels of IL-12–induced pSTAT4 were compared between healthy blood donors who were smokers (current or past) (n=20) and never-smokers (n=25) by Student’s t-test. IL-12, interleukin-12; pSTAT4, phosphorylated Signal Transducer and Activator of Transcription 4.
believe that the association of the IL12A risk allele, in addition to the STAT4 risk allele, with MI points to the importance of this pathway in the development of the comorbidity. Previous work has demonstrated that JAK-inhibitors efficiently block the increase in pSTAT4 levels, and ameliorate murine lupus as well as its associated vascular dysfunction. 19 39 Due to the potential therapeutic strategy of JAK-inhibitors for patients with SLE displaying an altered activity in this particular pathway, we believe that further studies of the effect of this pathway on development of CVE are warranted.

This study’s strength is the large, well-characterised discovery cohort, that results were validated in a second large cohort, and the analysis of healthy control cells, which confirmed that pSTAT4 levels are higher in smokers. In addition, the quality control of genetic data was rigorous, and the patients’ long mean follow-up time of 17 years allowed for many outcome variables such as MI to be recorded. There are, however, some limitations. First, our study is based on retrospective data and we lacked data on the year of smoking cessations. As patients who were past smokers at the last follow-up may have been active smokers at the time of their CVE, we could not analyse previous and current smoking separately. Second, we did not have data on number of pack-years, which may have generated more precise results. Third, the study includes only Scandinavian patients with SLE, and whether the associations are generalisable to patients of other ethnicities needs further investigation.

CONCLUSION

We demonstrate that smokers carrying the STAT4 risk allele are at an increased risk of MI and nephritis and that the IL12-STAT4 pathway may be important for the development of MI. Our results stress the importance of smoking cessation in SLE and particularly among those carrying this risk allele.

Author affiliations
1Department of Medical Sciences, Rheumatology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden
2Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linköping University, Linköping, Sweden
3Department of Rheumatology, Oslo University Hospital, Oslo, Norway
4Department of Clinical Sciences Lund, Rheumatology, Lund University, Skane University Hospital, Lund, Sweden
5Division of Rheumatology, Department of Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
6Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
7Department of Biomedicine, Aarhus University, Aarhus, Denmark
8Department of Rheumatology, Odense University Hospital, Odense, Denmark
9Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
10Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

Acknowledgements
We thank the patients and healthy volunteers for participating, clinicians and researchers contributing to the replication cohort and Majia-Leena Eloranta, Cane Yaka, Rezvan Kiani and Karolina Tandre.

Contributors
SR, DL and LR designed the study. SR, NH, JKS, AA, PP, CS, AJ, IG, A-CC, AMT, AV, AAB, ES, LR and DL collected the data for the discovery cohort. KL, AMT, AV, ØM and SJ collected the data for the replication cohort. SR, DL and LR analysed the data. SR, DL and LR wrote the manuscript. All authors revised the manuscript critically for important intellectual content and approved the final version of the manuscript.

Funding
This work was supported by grants from the Swedish Research Council for Medicine and Health (D0283001), the Swedish Rheumatism Association, King Gustav V’s 80-year Foundation, the Swedish Society of Medicine and the Ingered Johansson donation, Åke Wilberg’s foundation, Gustafsson’s foundation, Selander’s foundation, Norsk Reumatikerforbunds Forskningsfond, Pålhés legat og Stortuens legat and the Swedish Society for Medical Research (S20-0127).

Competing interests
None declared.


Uzair AH, Assaf AM, Abdalla SS. Correlations of Expression Levels of a Panel of Genes (IRFS, STAT4, TNFSF4, MECPR2, and TLR7) and Cytokine Levels (IL-2, IL-6, IL-10, IL-12, IFN-γ, and TNF-α) with Systemic Lupus Erythematosus Outcomes in Jordanian Patients. *Biomed Res Int* 2019:2019:1–11.


